

Appendix 9 (as supplied by the authors): Methodological quality of randomized controlled trials of long-acting insulin analogues in type 2 diabetes.

Study*	Jadad Score for:			Total Jadad Score	Allocation Concealment?	Blinding of Outcome Assessor?	Intent-to- Treat analysis?	Number of Patients	Dropouts N (%)
	Randomization	Double Blinding	Withdrawals and Dropouts						
Eliashewitz <i>et al.</i> , 2006 ⁹²	1	0	1	2	Unclear	No	Yes	481	19 (3.95)
Fonseca <i>et al.</i> , 2004 ¹²⁷	1	0	1	2	Unclear	NR	NR	100	7 (7)
Fritsche <i>et al.</i> , 2003 ¹²⁸	2	0	1	3	Unclear	NR	Yes	695	55 (7.91)
Haak <i>et al.</i> , 2005 ¹²⁹	1	0	1	2	Unclear	NR	Yes	505	34 (6.73)
Hermansen <i>et al.</i> , 2006 ⁹¹	1	0	1	2	Adequate	No	Yes	475	24 (5.05)
Massi Benedetti <i>et al.</i> , 2003 ¹³¹	2	0	1	3	Unclear	NR	Yes	570	46 (8.07)
Pan <i>et al.</i> , 2007 ¹⁰⁸	1	0	1	2	Unclear	No	No	444	49 (11.06)
Philis-Tsimikas <i>et al.</i> , 2006 ⁹⁹	1	0	1	2	Adequate	No	Yes	498	51 (10.24)
Raslova <i>et al.</i> , 2004 ⁹⁴	1	0	1	2	Unclear	No	Yes	394	16 (4.06%)
Riddle <i>et al.</i> , 2003 ¹³²	2	0	1	3	Unclear	NR	Yes	756	65 (8.6%)
Rosenstock <i>et al.</i> , 2001 ¹¹¹	1	0	1	2	Unclear	NR	Yes	518	49 (9.46%)
Wang <i>et al.</i> , 2007 ¹⁰⁹	1	0	0	1	Unclear	No	Yes	24	NR
Yki-Järvinen <i>et al.</i> , 2000 ¹³⁸	1	0	0	1	Unclear	NR	Yes	426	NR
Yki-Järvinen <i>et al.</i> , 2006 ¹³⁹	2	0	1	3	Unclear	NR	Yes	110	3 (2.73)
HOE 901/2004 Study Investigators Group, 2003 ¹⁴⁰	2	0	1	3	Unclear	NR	Yes	204	2 (0.98)

NR=not reported.

*Citations of the studies are listed in the main article, available at www.cmaj.ca/cgi/content/full/180/4/385.